← Eichor
Study identifier: NCT07010692 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Condition: Keratinocyte Carcinoma · Basal Cell Carcinomas · Squamous Cell Carcinoma  ·  Sponsor: Bruce Robinson, MD

PhasePhase 1/Phase 2
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.

This description comes directly from the study's public registry record.

Talk to the study team

Gillian Nanni, Research Coordinator, BS  ·  212-750-7121  ·  info@brucerobinsonmd.com

Always discuss trial participation with your own doctor first.

Locations (1)

Bruce Robinson, MDNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07010692